Effects of Writers, Erasers and Readers Within MiRNA-related M6A Modification in Cancers

Overview

Journal Cell Prolif

Date 2022 Sep 26

PMID 36162823

Authors

Huiru Feng

Xiaofei Yuan

Shuting Wu

Yue Yuan

Linchong Cui

Danfan Lin

Xiaohong Peng

Xiong Liu

Fan Wang

Affiliations

Soon will be listed here.

Abstract

Background: As one of the most abundant post-transcriptional mRNA modifications, N6-methyladenosine (m6A) has attracted extensive attention from scientists. Emerging evidence indicates that m6A modification plays a significant role in cancer-related signalling pathways. Existing research demonstrates that m6A modifications were also identified in miRNAs and contribute to cancer-related signalling pathways.

Methods: A literature retrieval has been performed to collect m6A-miRNA-related original articles published in recent years. Later, a systematic analysis has been conducted to abstract and classify the relationships between m6A modification and miRNAs, and their contributions to tumorigenesis and cancer development.

Results: Accumulating literature provides important insights into multiple relationships between m6A modifications and miRNAs. Mechanically, m6A writer and eraser alter pri-miRNAs m6A levels, and m6A readers could dually modulate pri-miRNAs processing and pri-miRNAs degradation. It is also been demonstrated that miRNAs impair m6A regulators' translation to influence m6A medication function in return. Aberrant expressions of m6A regulators and miRNAs could dysregulate proliferative, apoptosis, cell adhesion-related, and malignant transformation signalling pathways, and contribute to tumour occurrence and development.

Conclusion: This review summarizes the interrelationship between m6A modification and miRNAs; highlights the combined effects of each type of m6A regulator and miRNAs in cancers. These findings enhance our understanding of m6A-miRNAs' multiple interactions and significant modulatory role in tumorigenesis and progression.

Citing Articles

Recent Advances in the Mutual Regulation of m6A Modification and Non-Coding RNAs in Atherosclerosis.

Wang Y, Ling S, Feng H, Hua J, Han Z, Chai R Int J Gen Med. 2025; 18:1047-1073.

PMID: 40026815 PMC: 11871936. DOI: 10.2147/IJGM.S508197.

The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.

Shi T, Zhang H, Chen Y Cell Biosci. 2025; 15(1):27.

PMID: 39987091 PMC: 11846233. DOI: 10.1186/s13578-025-01368-z.

Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications.

Li P, Fang X, Huang D Eur J Med Res. 2025; 30(1):98.

PMID: 39940056 PMC: 11823136. DOI: 10.1186/s40001-025-02353-5.

New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy.

Li M, Tian H, Zhuang Y, Zhang Z Front Immunol. 2025; 16:1533940.

PMID: 39911396 PMC: 11794227. DOI: 10.3389/fimmu.2025.1533940.

Biosynthesis inhibition of miR-142-5p in a N-methyladenosine-dependent manner induces neuropathic pain through CDK5/TRPV1 signaling.

Li J, Guo Y, Zhu C, Wang D, Li Y, Hao X Cell Mol Biol Lett. 2025; 30(1):16.

PMID: 39891095 PMC: 11786349. DOI: 10.1186/s11658-025-00695-w.

References

Yi D, Wang R, Shi X, Xu L, Yilihamu Y, Sang J . METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression. Oncol Rep. 2020; 43(5):1375-1386. PMC: 7107905. DOI: 10.3892/or.2020.7515. View

Yang Z, Li J, Feng G, Gao S, Wang Y, Zhang S . MicroRNA-145 Modulates -Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the -Methyladenosine Binding YTH Domain Family 2 Protein. J Biol Chem. 2017; 292(9):3614-3623. PMC: 5339747. DOI: 10.1074/jbc.M116.749689. View

Zhou Z, Lv J, Yu H, Han J, Yang X, Feng D . Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer. 2020; 19(1):104. PMC: 7278081. DOI: 10.1186/s12943-020-01216-3. View

Croce C . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10(10):704-14. PMC: 3467096. DOI: 10.1038/nrg2634. View

Patil D, Chen C, Pickering B, Chow A, Jackson C, Guttman M . m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016; 537(7620):369-373. PMC: 5509218. DOI: 10.1038/nature19342. View

Knuckles P, Lence T, Haussmann I, Jacob D, Kreim N, Carl S . Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the mA machinery component Wtap/Fl(2)d. Genes Dev. 2018; 32(5-6):415-429. PMC: 5900714. DOI: 10.1101/gad.309146.117. View

Wei C, Gershowitz A, Moss B . 5'-Terminal and internal methylated nucleotide sequences in HeLa cell mRNA. Biochemistry. 1976; 15(2):397-401. DOI: 10.1021/bi00647a024. View

Dai D, Wang H, Zhu L, Jin H, Wang X . N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018; 9(2):124. PMC: 5833385. DOI: 10.1038/s41419-017-0129-x. View

Xu C, Liu K, Ahmed H, Loppnau P, Schapira M, Min J . Structural Basis for the Discriminative Recognition of N6-Methyladenosine RNA by the Human YT521-B Homology Domain Family of Proteins. J Biol Chem. 2015; 290(41):24902-13. PMC: 4598999. DOI: 10.1074/jbc.M115.680389. View

10.

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

11.

Hsu P, Zhu Y, Ma H, Guo Y, Shi X, Liu Y . Ythdc2 is an N-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017; 27(9):1115-1127. PMC: 5587856. DOI: 10.1038/cr.2017.99. View

12.

Xu Y, Ye S, Zhang N, Zheng S, Liu H, Zhou K . The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (Lond). 2020; 40(10):484-500. PMC: 7571404. DOI: 10.1002/cac2.12075. View

13.

Du C, Lv C, Feng Y, Yu S . Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res. 2020; 39(1):223. PMC: 7576758. DOI: 10.1186/s13046-020-01735-3. View

14.

Hu H, Kong Q, Huang X, Zhang H, Hu K, Jing Y . Longnon-coding RNA BLACAT2 promotes gastric cancer progression via the miR-193b-5p/METTL3 pathway. J Cancer. 2021; 12(11):3209-3221. PMC: 8100803. DOI: 10.7150/jca.50403. View

15.

Ma L, Chen T, Zhang X, Miao Y, Tian X, Yu K . The mA reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function. Redox Biol. 2020; 38:101801. PMC: 7691619. DOI: 10.1016/j.redox.2020.101801. View

16.

Yuan S, Tang H, Xing J, Fan X, Cai X, Li Q . Methylation by NSun2 represses the levels and function of microRNA 125b. Mol Cell Biol. 2014; 34(19):3630-41. PMC: 4187725. DOI: 10.1128/MCB.00243-14. View

17.

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

18.

Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C . N-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020; 11(10):836. PMC: 7547657. DOI: 10.1038/s41419-020-03049-w. View

19.

Shi H, Wei J, He C . Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019; 74(4):640-650. PMC: 6527355. DOI: 10.1016/j.molcel.2019.04.025. View

20.

Zhu H, Gan X, Jiang X, Diao S, Wu H, Hu J . ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019; 38(1):163. PMC: 6463658. DOI: 10.1186/s13046-019-1159-2. View